Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Heart, Lung, and Blood Institute (NHLBI) |
---|---|
Information provided by: | National Heart, Lung, and Blood Institute (NHLBI) |
ClinicalTrials.gov Identifier: | NCT00000556 |
To compare two standard treatment strategies for atrial fibrillation: ventricular rate control and anticoagulation vs. rhythm control and anticoagulation.
Condition | Intervention | Phase |
---|---|---|
Arrhythmia Atrial Fibrillation Cardiovascular Diseases Heart Diseases |
Drug: amiodarone Drug: sotalol Drug: propafenone Drug: flecainide Drug: quinidine Drug: moricizine Drug: disopyramide Drug: procainamide Drug: adrenergic beta antagonists Drug: verapamil Drug: diltiazem Drug: digoxin Procedure: catheter ablation Device: pacemaker, artificial |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized |
Study Start Date: | March 1995 |
Estimated Study Completion Date: | September 2002 |
Ages Eligible for Study: | 65 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Elderly men and women with atrial fibrillation and other risk factors for stroke.
Study ID Numbers: | 100 |
Study First Received: | October 27, 1999 |
Last Updated: | December 1, 2005 |
ClinicalTrials.gov Identifier: | NCT00000556 |
Health Authority: | United States: Federal Government |
Heart Diseases Amiodarone Sotalol Propafenone Verapamil Quinidine Diltiazem |
Moricizine Flecainide Digoxin Atrial Fibrillation Procainamide Disopyramide Arrhythmias, Cardiac |
Anti-Infective Agents Antiprotozoal Agents Vasodilator Agents Neurotransmitter Agents Cholinergic Antagonists Molecular Mechanisms of Pharmacological Action Adrenergic Agents Physiological Effects of Drugs Enzyme Inhibitors Cardiovascular Agents Adrenergic alpha-Antagonists |
Cholinergic Agents Pharmacologic Actions Muscarinic Antagonists Antimalarials Antiparasitic Agents Pathologic Processes Therapeutic Uses Cardiovascular Diseases Adrenergic Antagonists Anti-Arrhythmia Agents |